KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Amortization of Deferred Charges (2020 - 2025)

Historic Amortization of Deferred Charges for Esperion Therapeutics (ESPR) over the last 6 years, with Q3 2025 value amounting to $4.6 million.

  • Esperion Therapeutics' Amortization of Deferred Charges rose 92460.85% to $4.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.2 million, marking a year-over-year increase of 42122.94%. This contributed to the annual value of $1.5 million for FY2024, which is 1172.66% down from last year.
  • Latest data reveals that Esperion Therapeutics reported Amortization of Deferred Charges of $4.6 million as of Q3 2025, which was up 92460.85% from $3.7 million recorded in Q2 2025.
  • In the past 5 years, Esperion Therapeutics' Amortization of Deferred Charges ranged from a high of $4.6 million in Q3 2025 and a low of $172000.0 during Q4 2024
  • Over the past 5 years, Esperion Therapeutics' median Amortization of Deferred Charges value was $417000.0 (recorded in 2023), while the average stood at $811736.8.
  • Its Amortization of Deferred Charges has fluctuated over the past 5 years, first plummeted by 7662.26% in 2021, then skyrocketed by 92460.85% in 2025.
  • Over the past 5 years, Esperion Therapeutics' Amortization of Deferred Charges (Quarter) stood at $407000.0 in 2021, then increased by 1.72% to $414000.0 in 2022, then grew by 4.11% to $431000.0 in 2023, then plummeted by 60.09% to $172000.0 in 2024, then soared by 2562.79% to $4.6 million in 2025.
  • Its Amortization of Deferred Charges stands at $4.6 million for Q3 2025, versus $3.7 million for Q2 2025 and $699000.0 for Q1 2025.